echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > The Lancet publishes the phased results of the Sichuan University drug weight loss clinical research

    The Lancet publishes the phased results of the Sichuan University drug weight loss clinical research

    • Last Update: 2021-12-30
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

      On December 9, 2021, The Lancet, one of the "Four Major Journals of Clinical Medicine", published online the phased results of a clinical study on weight loss with drugs in West China Hospital of Sichuan University.
    The study systematically estimated different weight loss The efficacy and safety of drugs used in the treatment of weight loss in overweight and obese adults

    .

      Shi Qingyang, research assistant in the Evidence-Based Evaluation and Quick Guide Laboratory of China Evidence-Based Medicine Center, West China Hospital, Sichuan University, and Wang Yang, a 2021 professional master's student in the Department of Endocrinology and Metabolism, West China Hospital, Sichuan University, are the co-first authors of the paper, and the Department of Endocrinology and Metabolism, West China Hospital, Sichuan University /Associate Professor Li Sheyu, Evidence-based Evaluation and Quick Guide Research Office, China Evidence-Based Medicine Center, is the corresponding author, and West China Hospital of Sichuan University is the only first author and corresponding author unit
    .


     

      Obesity is an important risk factor for endocrine metabolism and cardiovascular diseases, and has long been at the forefront of disease burden
    .
    Although life>
    .
    As an important supplement to life>
    .
    However, the weight-loss effects and risks of weight-loss drugs have long been controversial.
    In recent years, new weight-loss drugs have appeared, and weight-loss drugs have been "taken off the shelves" by the medical management department due to safety issues

    .
    The team of Associate Professor Li Sheyu from West China Hospital of Sichuan University adopted the latest evidence-based medicine research methods and innovative results visualization model through systematic review and quality evaluation of existing clinical trials of major weight-loss drugs, and independently developed new ones based on the actual situation of the research.
    Drug classification model found that phentermine/topiramate and GLP-1 receptor agonists are the most significant weight loss drugs

    .
    The addition of phentermine/topiramate on the basis of life>
    .
    Among GLP-1 receptor agonists, on the basis of life>
    .
    In terms of adverse reactions, 61 people will give up taking phentermine/topiramate for every 1,000 people who use phentermine/topiramate for one year, while simegliutide is 44 people

    .
    Clinicians and patients can quickly select weight loss drugs through the intuitive information provided by the chart

    .
    The results of this study will subsequently support the first clinical decision-making recommendation of Huaxi's rapid recommendation of weight-loss drugs, and the possible selection model of weight-loss drugs, thereby providing a reference for the treatment options of people suffering from weight-related problems around the world

    .

     



     

      Invited by the editorial office of Lancet, Professor CW le Roux, University College Dublin, Ireland, highly praised the impact of this research on clinical practice
    .
    Before the study was officially published, it had been cited by many high-level journals such as Lancet, and its preprint has repeatedly ranked among the top ten in various fields such as obesity and public health

    .
    This research is one of the branch tasks of the first "Quick Recommendation of West China" project in West China Hospital of Sichuan University

    .
    From the Norwegian MAGIC Evidence Ecology Foundation, Canada McMaster University, Tianjin University of Traditional Chinese Medicine, Lanzhou University, Peking University, Xi'an Jiaotong University, West China School of Public Health of Sichuan University, West China Hospital Geriatrics Center, Rehabilitation Medicine, Nursing Department, Pharmacy , Urology clinicians, methodologists, master graduate students and undergraduate students participated in the research

    .
    In addition, the research has also received strong support from a guideline expert group composed of more than 20 clinical experts engaged in obesity diagnosis and treatment from all over the country, and the 135 project of West China Hospital of Sichuan University

    .
    This study is another landmark stage achievement since the MAGIC China Center Guidelines Evaluation and Rapid Recommendation Laboratory of Cochrane China Center of West China Hospital led the formulation and release of the International Diabetes Clinical Practice Guidelines in May 2021

    .

     

      Article link:

     

      https://  

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.